Growing Industrial Commercial Electrical Contractor

This painting company has been stable, but they have seen sustained growth and have been one of the fastest growing small business painting companies in the Vancouver/Portland area. Starting in 2013, annual had already eclipsed half a million by 2019. With a work-from-home office, this business provides the ability to manage safely out of your own home or to be able to choose your ideal location to rent. Strong customer ratings and consistently high levels of service have made this an ideal business for anyone looking to establish a presence in the painting industry or to expand your current painting business territory and customer base. Detailed Information Employees:2 FTE Support & Training: Seller will negotiate a transition period Reason for Selling: Relocation

Fully ACA-focused portfolio with 696 active members generating $433K in premium and $60K in annual commissions. Ambetter represents ~70% of total volume, with top-producing states including TX, FL, MI, OH, AZ, and TN. Buyers gain immediate bonus potential — even at one-third retention, estimated one-time bonuses total $23K+, and at 50% retention approximately $35K. The portfolio also delivers steady $20 PMPM recurring cash flow with retention upside. This is a Book of Business-only sale (no employees or assets). Verified client data, carrier-approved transfers, and up to 60 days of transition support included. Strong upside for groups looking to expand ACA market share and recurring revenue. NDA is required to secure comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

Our client is offering a next generation, patented medical device for the treatment of internal hemorrhoids. The procedure is painless, non-invasive, requires no anesthesia, is conducted in under 2 minutes, and can be performed in any medical setting: a doctor's office, a surgery center, an endo suite, or a hospital. Our client's product is a small, disposable, medical device that eliminates hemorrhoids. A physician uses this device by deploying a tiny rubber band on the base of the hemorrhoid. This procedure is known as rubber band ligation, and it is the #1 recommended treatment for internal hemorrhoids by the American College of Gastroenterology. Patients no longer need to use ineffective creams or receive painful, invasive surgery. Our client's device offers a permanent solution for their hemorrhoids. The device is currently manufactured in the USA through an FDA approved, ISO 13485 contract manufacturer, who specializes in medical devices. The device is sold directly to physicians of different specialties, including gastroenterologists, colorectal surgeons, GYNs, urologists and primary care physicians. The biggest targeted audience are gastroenterologists. NDA is required to secure comprehensive Confidential Information Memorandum. Growth and epansion: Nearly half of adults over the age of 50 will develop symptomatic hemorrhoids. In the U.S. alone, an estimated 60,000,000 people have experienced hemorrhoid symptom(s) at some point in their lives. Annually, over 20,000,000 people in the U.S. use an over-the-counter hemorrhoid treatment and 75% report a reoccurrence. These patients no longer need to use ineffective creams or receive painful, invasive surgery. Our client's device offers a permanent solution for their hemorrhoids. Financing is if the price and deal structure is right, and support and training is provided as required. Facilities are Outlined in CIM. Reason for selling is that the owners wish to move on to other projects.

Patented Universal Tumor-Targeting Drug Delivery Platform Co. This pharmaceutical company has developed and patented a universal tumor-targeting drug-delivery platform that can improve the safety and efficacy of many existing chemo treatments, with the ability to target numerous different types of cancer. The technology encapsulates existing FDA-approved drugs inside lipid nanoparticles (liposomes or emulsions) coated with patented human-sourced antinuclear antibodies (ANA). The lipid nanoparticle provides long-term storage stability of the drug and controlled release of the drug over time at body-temperature, and is expected to improve the safety and efficacy profile of the drug, including passive accumulation at the tumor while not harming normal tissues. The Company's ANA, sourced from lupus patients, binds to nuclear material present in abundance in areas of necrosis (dead / ruptured cells) present in and around all solid tumors, thus anchoring the drug-filled nanoparticles at the tumor where the nanoparticle is designed to slowly release the drug directly on the tumor for more effect. As the Company's ANA is not tumor-marker specific, but rather targets necrosis present in solid tumors, the technology is designed to "universally" target many different types of cancer including breast cancer, lung, ovarian, colon, prostate, etc., as well as rare childhood cancers. The Company completed a successful proof-of-concept study at Children's Hospital using Ewing's Sarcoma transplanted in immunodeficient mice. Treatment with the Company's forumlation significantly inhibited tumor growth and extended survival times compared to control mice receiving no treatment or treatment with plain liposomal doxorubicin. The Company has been granted Orphan Drug Designation by the FDA on 2 of the lead drug formulations, providing FDA fee waivers, priority review, and 7-years exclusivity upon market approval. The orphan pathway also enables the potential for New Drug Approval after successful completion of Phase 2 studies, with Phase III data collected while in the market, thus significantly lowering the time and cost to market approval. This same drug inside the Company's tumor targeting delivery system will likely have potential to treat other pediatric cancers, and/or cancers in larger adult populations. As the Company's platform and ANA has the potential to improve the safety and efficacy of many existing FDA approved drugs or even compounds in development, the Company anticipates the potential for multiple licensing agreements with multiple pharmaceutical companies seeking to improve their existing portfolio and extend patient life as they advance into clinical stage. And as it may be possible to file for New Drug Approval following successful Phase II studies, the Company anticipates licensing potential at early clinical stage. Multiple exit opportunities exist with high impact & high ROI. The Company is seeking a supportive capital partner to maintain momentum up to $20M. Funding will be used to advance the lead drug through formal Investigational New Drug enabling studies towards New Drug Approval; estimating $3-5 Million now to advance into clinical studies. Preclinical / animal studies estimate ($3 - 5 Million and 12-18 months); follwed by potential combined Phase I-II clinical study in a rare cancer (approximately 2-3 years and $10M) to potential New Drug Approval, plus additional capital to advance additional drugs in the pipeline simultaneously, thus adding tremendous value to the Company's valuation. Valuations of pharma companies often exceed $100 Million valuation at Phase I (approx. 18 months), and New Drug Approval can exceed valuations above $1 Billion. The Company has numerous, improved high-impact cancer drugs advancing with proper support. NDA is required for comprehensive Confidential Information Memorandum crafted by ProNova Partners. Detailed Information Competition: Trying to improve existing therapies and develop novel approaches to hard to treat cancers. Growth & Expansion: Huge market potential. Financing: If the price and deal structure is right. Support & Training: Transition team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .

Our client offers a NFT fantasy franchise sports platform, built on blockchain technology, that introduces true in-game ownership of franchises, teams, and players through the use of NFTs (Non-Fungible Tokens). Unique to our client, customers will own their franchise and their players indefinitely, unless they wish to sell, trade, rent, lease, or perform some other smart contracts. Our client's NFTs are made possible and exceptional by confirming ownership, providing secure transactions, and ensuring that no asset can be duplicated. Our client's product strives to mimic real professional leagues as closely as possible. This innovative platform can be used for all sports around the entire planet! The platform is a fantasy franchise sports game confirms the owner of all assets involved: from franchises to active players; all the way down to the lowest prospect. It also confirms each and every activity. Top 10 Features: 1. Create an account. 2. Once a user has an account, they can either create a fantasy franchise league by paying a fee to receive sports teams and their respective players or receive one by transfer or purchase of a team in an existing league. 3. Any user can stake Sports Coin (SPC) on any real or publicly available fantasy franchise sports game to earn SPC based on the staked players or teams' performance. 4. Players can have one place to see all the relevant stats they need to predict games or follow their favorite players. 5. Free text and soon free audio/video calls. 6. History gives the ENTIRE transaction history. 7. Verify identity using BasisID. 8. Trade, transact, or earn SPC from fantasy franchise NFTs 9. Store Bitcoin/Ethereum to buy Score coin 10. Use the Lightning/Raiden Network for instant free transactions Our client's software is 'ready to go;' and is operating with active customers and net income. NDA is required to secure comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Detailed Information Facilities: N/A Growth & Expansion: Unlimited worldwide. Financing: Sellers will consider, BitCoin preferred Support & Training: As needed specific terms for transition support can be negotiated. The Seller wishes to facilitate a successful and smooth transfer of the Business. Reason for selling: Expansion.

Our client developed and operates a multi-market high-demand system capable of identifying criminal subjects in seconds. Access to the cloud-based software is subscription-based with packages ranging from $35,000 to $300,000 annually. The system generates recurring revenue from major retailers. Our client's database is fed with crime and criminal data from over 28,000 sources that update and add new data to their system every day. A global technology agreement was recently signed by a major worldwide electronics manufacturer to integrate our client's system. This significant agreement with the major worldwide electronics manufacturer expands the system from single-enterprise sales to mass-market injection via this new customer's global customer base. The enterprise was designed to bridge the long-standing gap between surveillance video and subject identification and create a next-generation system for subject intelligence. The founder tells us: 'We spent significant time and resources to identify over 28,000 data source points and go through the process to obtain, extract, scrub, and continually update records. Our system and process continued to rapidly develop, allowing further increases in data digestion while completely automating the process. We remain the largest private database of criminals in the world. We developed a multi-market high-demand system capable of identifying criminal subjects in seconds. Whether identifying subjects from surveillance video, home security cameras, video doorbell cameras, or conducting compliance and risk mitigation, our solution and its 70 million+ database is a market-first product with no competition and is used by a variety of Fortune 500 blue-chip customers. The signing of a major worldwide electronics manufacturer to a global technology partnership will add our system to their security products, creating a mass-market injection and significant ARR stream.' With a sales, marketing, and business development team comprised of only 2 people, our client focused initially on penetrating the difficult and highly competitive market of loss prevention within Fortune 500 retailers. After the proprietary system demonstrated a successful track record in identifying subjects and deterring criminal activity, our client gained immediate visibility and has since gained nearly a dozen of the world's largest retailers as clients. Our client has disrupted antiquated identification processes within several of the largest markets, attracting the attention of global manufacturers such as the major worldwide electronics manufacturer's willing to integrate their technology. Our client developed a SaaS system, which provides its '4 I's' Intelligence, Information, Investigation, and Identification. The SaaS is a completed system and is fed with crime and criminal data from over 28,000 sources that update and add new data to the system every day. Access to the cloud-based software is subscription-based with packages ranging from $35,000 to $300,000 annually. Our client's technology has been implemented by many of the largest companies in the world and is currently being integrated by one of the largest technology manufacturers in the world. The strategy is effective, and the reach of the technology is poised to be further expanded. Our client invented and made operational multiple processes and new technology. The system is not only completed and automated, but also proven in the marketplace. One of the achievements worthy of note is that our client's system was responsible for the largest Organized Retail Crime bust in US history. Our client's core competencies and strengths include the highly developed system with ownership of the largest private database of criminal subjects in the world, existing blue-chip customers, a global technology contract with a major worldwide electronics manufacturer, and a technology platform that is extremely valuable in multiple other markets that have not yet been approached. Our client's Intelligence obtains its database data from over 28,000 county, state, federal, and regulatory agency sources. Our client has automated the data digestion process to upload new records, and search/verify changed records several times per day. Once new and or changed data is recognized, an automated process will retrieve the data, categorize, and then implement into our client's system. Our client owns all processes, and websites which they will transfer in full to a buyer. Our client's 'ready to go,' profitable tech, and relationships will enable a buyer to be up and running immediately. NDA is required {LINK ABOVE} to secure comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Detailed Information Facilities: N/A Growth & Expansion: See the CIM for details Financing: Offers and investment will be considered Support & Training: As needed specific terms for transition support can be negotiated. The Seller wishes to facilitate a successful and smooth transfer of the Business. Reason for Selling: To allow the business to rapidly expand world-wide

Confidential Information Memorandum (CIM) available upon receipt of our short online NDA. * It is estimated that the marketplace for connected cars and automobile data is will reach $400BN by 2030. * There are currently ~280MM registered automobiles in the US today with ~65MM of them being connected cars * The Company has created a process that while working with 3rd party Companies in the space and simultaneously creating a near proprietary technology is able to harness processes related to car data, thereby creating an opportunity for Companies looking to enter the aftermarket space for consumers and/or enterprises already in the automobile space, * Ideally this would be an add-on solution for any Company that is in the fleet-auto space, or looking to create an expansive and/or sweeping platform for the Consumer space NDA is required to secure comprehensive Confidential Information Memorandum (CIM). Detailed Information: Facilities: Home Based Competition: Few if any Growth & Expansion: Ample Financing: Depending on offer and structure may be acceptable minimal if any Support & Training: As needed. Reason for Selling: Existing opportunities

Our client operates a lean, high-margin B2B lead-generation platform dedicated to the Internet of Things sector. By leveraging a permission-based community of over 60,000 vetted IoT decision-makers and a LinkedIn Group of 20,000+ approved professionals, they deliver turnkey sponsored webinars, white-paper campaigns, and targeted email blasts—providing technology vendors with consistently qualified leads while maintaining minimal overhead through a fully remote, contractor-driven model. NDA is required for comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.